All Releases
 |
Aastrom Announces Treatment of Final Patient in IMPACT-DCM Surgical Clinical Trial
03-09-10
|
12.3 KB |
|
| |
ANN ARBOR, Mich., March 9, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM. Treated at Emory Univ...
|
|
Aastrom Regains Compliance With NASDAQ Minimum Bid Requirement
03-04-10
|
10.4 KB |
|
| |
ANN ARBOR, Mich., March 4, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing under NASDAQ Listing Rule ...
|
|
Aastrom Reports Interim Results From Critical Limb Ischemia Trial
02-24-10
|
11.7 KB |
|
| |
Study meets composite endpoint of reduction in time to treatment failure with statistical significance Company concludes patient enrollment early to accelerate study completion and Phase 3 planning Aastrom to hold investor conference call at 9 a.m. ET to discuss results
ANN ARBOR, Mich., Feb. 24, 2010 (GLOBE NEWSWIRE) ...
|
|
Aastrom One-for-Eight Reverse Stock Split Now Effective
02-18-10
|
9.1 KB |
|
| |
ANN ARBOR, Mich., Feb. 18, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) today reported that its previously announced one-for-eight reverse stock split of the company's issued and outstanding common shares is now effective. This reverse split is intended to increase the per share trading price of Aastrom's common stock to satisf...
|
|
Aastrom Reports Second Quarter Fiscal Year 2010 Financial Results
02-10-10
|
19.1 KB |
|
| |
ANN ARBOR, Mich., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today reported financial results for its second fiscal quarter ended December 31, 2009, and also announced progress in its late-stage clinica...
|
|
Aastrom Announces One-for-Eight Reverse Stock Split
02-09-10
|
9.3 KB |
|
| |
ANN ARBOR, Mich., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences (Nasdaq:ASTM) announced today that its board of directors has approved a one-for-eight reverse stock split of the company's common stock effective on February 18, 2010. The company has filed an amendment to its articles of incorporation to effect the reverse stock split, which ...
|
|
Aastrom Biosciences Announces Closing of Unit Offering
01-21-10
|
11.3 KB |
|
| |
ANN ARBOR, Mich., Jan. 21, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced the closing of its previously announced underwritten public offering from which the Company received approximately $12.4 million in net pro...
|
|
Aastrom Biosciences Announces Pricing of Unit Offering
01-15-10
|
10.8 KB |
|
| |
ANN ARBOR, Mich., Jan. 15, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced the pricing of its previously announced underwritten public offering of 46,154,000 units at a public offering price of $0.26 per unit. Each...
|
|
Aastrom Biosciences Announces Proposed Public Offering of Units
01-14-10
|
10.3 KB |
|
| |
ANN ARBOR, Mich., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that it intends to offer to sell, subject to market and other conditions, units consisting of shares of its common stock, Class A warrants ...
|
|
Aastrom Biosciences Shareholders Approve All 2009 Proxy Proposals
12-21-09
|
11.0 KB |
|
| |
ANN ARBOR, Mich., Dec. 21, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that shareholders of the Company approved all five proxy proposals at the Annual Meeting of Shareholders held December 14, 2009. Af...
|
|
NASDAQ Hearings Panel Grants Exception Period to Aastrom Based on Request to Remain Listed on the NASDAQ Stock Market
12-09-09
|
10.9 KB |
|
| |
ANN ARBOR, Mich., Dec. 9, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that the NASDAQ Hearings Panel (Panel) has granted the Company's request to remain listed on the NASDAQ Stock Market (NASDAQ) until ...
|
|
Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders
12-09-09
|
8.8 KB |
|
| |
Ann Arbor, MI, December 9, 2009 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast:
What:
Aastrom Biosciences Fiscal Year 2009 Annual Meeting of Shareholders
...
|
|
Updates and Results From Aastrom's Vascular Program Presented at an American Heart Association Satellite Symposium
11-16-09
|
13.4 KB |
|
| |
ANN ARBOR, Mich., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced that two oral presentations regarding the Company's vascular clinical program were given Sunday evening at an American Heart Association ...
|
|
Interim Results From Aastrom's IMPACT-DCM Cardiac Trial Presented at The American Heart Association Meeting
11-16-09
|
14.3 KB |
|
| |
ANN ARBOR, Mich., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that Amit N. Patel, M.D., M.S., Associate Professor of Surgery at the University of Utah School of Medicine and the National Princi...
|
|
Aastrom to Initiate Second Phase II Clinical Trial for Treatment of Severe Chronic Heart Failure
11-10-09
|
11.1 KB |
|
| |
ANN ARBOR, Mich., Nov. 10, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that the Company will initiate its second clinical trial for the treatment of dilated cardiomyopathy (DCM), a severe disease associated wit...
|
|
Aastrom Biosciences Reports First Quarter Fiscal Year 2010 Financial Results
11-06-09
|
19.2 KB |
|
| |
ANN ARBOR, Mich., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today reported financial results and operational updates for the first fiscal quarter ended September 30, 2009. Aastrom continues to operate in a capital-ef...
|
|
Harold C. Urschel, Jr., M.D. Joins Aastrom Biosciences' Board of Directors
10-20-09
|
11.4 KB |
|
| |
ANN ARBOR, Mich., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that Harold C. Urschel, Jr., M.D., has been elected to the Company's Board of Directors.
Dr. Urschel is currently Chair of Cardiovascula...
|
|
Aastrom Receives Letter From NASDAQ Regarding Continued Non-Compliance With Minimum Bid Price Rule
10-07-09
|
9.7 KB |
|
| |
ANN ARBOR, Mich., Oct. 7, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, announced today that it received a Staff Determination letter from the NASDAQ Stock Market (NASDAQ) on October 2, 2009 indicating that the Company has not r...
|
|
Aastrom Biosciences to Present At Maxim Group Growth Conference
09-24-09
|
8.3 KB |
|
| |
ANN ARBOR, Mich., Sept. 24, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that George Dunbar, President and Chief Executive Officer, will present at the Maxim Group Growth Conference. The conference will be he...
|
|
Update On Aastrom's Cardiovascular Programs to be Presented At Transcatheter Cardiovascular Therapeutics Annual Meeting by Amit N. Patel, M.D.
09-22-09
|
12.4 KB |
|
| |
ANN ARBOR, Mich., Sept. 22, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced today that Dr. Amit N. Patel, Associate Professor of Surgery at the University of Utah School of Medicine and National Principal Investigator...
|
|
|
Print page |
Email page
